中国神经再生研究(英文版) ›› 2019, Vol. 14 ›› Issue (9): 1517-1518.doi: 10.4103/1673-5374.255963

• 观点:脑损伤修复保护与再生 • 上一篇    下一篇

λ-氨基丁酸A受体拮抗剂S44819在小鼠大脑中动脉闭塞模型中的临床前概念和结果

  

  • 出版日期:2019-09-15 发布日期:2019-09-15

Preclinical concepts and results with the GABAA antagonist S44819 in a mouse model of middle cerebral artery occlusion

Dirk M. Hermann 1, Barbara Saba 2, Aurore Sors 2, Claudio L. Bassetti 3   

  1. 1 Departments of Neurology, University Hospital Essen, Essen, Germany;
    2 Institut de Recherches Internationales Servier, Suresnes, France;
    3 University Hospital (Inselspital) Berne, Berne, Switzerland
  • Online:2019-09-15 Published:2019-09-15
  • Contact: Dirk M. Hermann, MD, dirk.hermann@uk-essen.de.
  • Supported by:

    Supported by Institut de Recherches Internationales Servier, Suresnes, France and Deutsche Forschungsgemeinschaft (HE3173/3-1 and HE3173/11-1, to DMH).

Abstract:

Recent advancements in recanalizing therapies, i.e., the combination of thrombolytic drugs with interventional thrombectomy, have considerably improved neurological outcome in ischemic stroke patients. Despite this progress, the large majority of stroke patients still exhibit neurological deficits in the long run, and ischemic stroke continues to be the most frequent cause of long-term disability. Hence, there is an unmet need for therapies that allow enhancing neurological recovery and brain plasticity in the post-acute stroke phase. Preclinical studies, e.g., delivering growth factors or neural precursor cells (NPC), have shown that brain plasticity can be successfully stimulated in the post-acute stroke phase, resulting in functional neurological improvements. These findings raised the question whether it is possible to promote neurological recovery and brain plasticity in stroke patients.